Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
暂无分享,去创建一个
Prateek Sharma | John J Vargo | Sachin Wani | Amit Rastogi | Neil Gupta | Ajay Bansal | R. Sampliner | D. Lieberman | A. Rastogi | A. Bansal | Prateek Sharma | G. Falk | P. Thota | B. Cash | S. Wani | N. Gupta | S. Gaddam | J. Horwhat | J. Vargo | S. Mathur | A. Higbee | Mandeep Singh | G. Balasubramanian | David A Lieberman | Richard E Sampliner | Brooks D Cash | Gary W Falk | Srinivas Gaddam | Mandeep Singh | Sharad C Mathur | Gokulakrishnan Balasubramanian | Prashanthi Thota | April D Higbee | John D Horwhat | Patrick E Young | P. Young | Mandeep Singh
[1] H. El‐Serag,et al. Temporal trends (1973–1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? , 2003, American Journal of Gastroenterology.
[2] H. Welch,et al. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. , 2005, Journal of the National Cancer Institute.
[3] J. Goldblum,et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. , 2011, Gastroenterology.
[4] M. Canto,et al. Predicting Neoplastic Progression in Barrett's Esophagus. , 2010, Annals of gastroenterology & hepatology.
[5] R. Playford. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus , 2006, Gut.
[6] Prateek Sharma,et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. , 2011, Gastroenterology.
[7] K. Behrns,et al. Incidence of Adenocarcinoma among Patients with Barrett's Esophagus , 2012 .
[8] Prateek Sharma,et al. Clinical practice. Barrett's esophagus. , 2009, The New England journal of medicine.
[9] Kenneth K Wang,et al. Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.
[10] D. Sautereau,et al. French Society of Digestive Endoscopy SFED guideline: monitoring of patients with Barrett’s esophagus , 2007, Endoscopy.
[11] E. Kuipers,et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study , 2010, Gut.
[12] Prateek Sharma,et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. , 2011, Gastroenterology.
[13] R. Sampliner,et al. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus , 1998, American Journal of Gastroenterology.
[14] Douglas K Rex,et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. , 2012, Gastroenterology.
[15] H. El‐Serag,et al. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? , 2003 .
[16] E. Kuipers,et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] Robert H Fletcher,et al. Guidelines for Colonoscopy Surveillance after Polypectomy: A Consensus Update by the US Multi‐Society Task Force on Colorectal Cancer and the American Cancer Society * , † , 2006, Gastroenterology.
[18] Amy Wang,et al. M1104 Predicting High-Grade Dysplasia (HGD) and Esophageal Adenocarcinoma (EAC) in Patients With Non-Dysplastic Barrett's Esophagus (BE): Results From a Large, Multicenter Cohort Study , 2010 .
[19] R. Sampliner,et al. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus , 2002, American Journal of Gastroenterology.
[20] A. Lindgren,et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.
[21] D. Faigel,et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. , 2006, Gastrointestinal endoscopy.
[22] J K Greenson,et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. , 2001, Human pathology.
[23] A. Rastogi,et al. Feasibility of MicroRNAs as Biomarkers for Barrett's Esophagus Progression: A Pilot Cross-Sectional, Phase 2 Biomarker Study , 2011, The American Journal of Gastroenterology.
[24] A. Gavin,et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. , 2011, Journal of the National Cancer Institute.
[25] D. Ransohoff,et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. , 1983, Human pathology.
[26] Amy Wang,et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[27] M F Dixon,et al. The Vienna classification of gastrointestinal epithelial neoplasia , 2000, Gut.